LYVE1 and neoplasm: As shown in Fig. 6a, YL529 remarkably decreased the amount of lymphangiogenesis in tumor tissues at 150 mg/kg for 14 days in VEGF-D-LL/2 tumor syngeneic model, as indicated by the LYVE-1 staining (34.71 % higher than the vehicle group in VEGF-D-LL/2 muscle model).